

01-99000-07

Original Effective Date: 08/15/01

Reviewed: 02/26/26

Revised: 03/15/26

## Subject: Chelation Therapy

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities.

**Summary and Analysis of Evidence:** UpToDate review “Prevention of cardiovascular disease events in those with established disease (secondary prevention)” (Henneken, Lopez-Sendon; 2025) states, “(t)he totality of evidence does not support chelation therapy in patients with coronary artery disease (CAD). As an example, in the 2024 Trial to Assess Chelation Therapy 2 (TACT2) of 959 participants with diabetes and prior myocardial infarction (MI), ethylenediaminetetraacetic acid-based chelation reduced blood lead levels but was not superior to placebo in reducing the composite endpoint of death, recurrent MI, stroke, coronary revascularization, or hospitalization for angina (35.6 versus 35.7 percent; hazard ratio [HR] 0.93; 95% CI 0.76-1.16) or any of the individual component endpoints. UpToDate review “Autism spectrum disorder in children and adolescents: Complementary and alternative therapies” (Hale, Harris; 2025) states, “(a)utism spectrum disorder (ASD) is a neurodevelopmental disorder with an incompletely understood etiology and no known cure. Many caregivers of children with ASD seek both conventional and complementary and alternative (CAM) therapies as part of the process of understanding and accepting the diagnosis. Few CAM therapies have been proven effective/ineffective or safe/unsafe in controlled trials. Given the uncertainty, the clinician and family must weigh the unknown benefit against the potential risks, which include competition with validated treatment for time, effort, and financial resources. We strongly discourage CAM therapies with unknown benefits and potential risks in the treatment of ASD. These therapies include ... chelation ...” Vezzoli et al (2023) studied the efficacy of an antioxidant treatment (calcium disodium ethylenediaminetetracetic acid-EDTA) chelation therapy

associated with a micronutrient complex in MS patients. A total of 20 MS patients and 20 healthy subjects, enrolled as a control group (CTR), were recruited. They measured the plasma ROS production and total antioxidant capacity (TAC) by a direct assessment using Electron Paramagnetic Resonance; activities of the antioxidant system (thiols' redox status and enzymes); and the urinary presence of biomarkers of oxidative stress by immunoenzymatic assays. They also evaluated the levels of inflammation by plasmatic cytokines (TNF $\alpha$ , IL-1 $\beta$ , and IL-6) and assessed the sICAM levels, as well as the nitric oxide (NO) catabolism and transthyretin (TTR) concentration. Comparing CTR and MS, in the latter ROS production, oxidative damage, inflammatory biomarkers, and no metabolite concentrations results were significantly higher, while TAC was significantly lower. The authors concluded "(b)y preventing or reducing oxidative damage, we may potentially prevent or delay neurodegeneration as a core substrate of disability. The present finding of the adopted treatment causing downregulation of inflammatory expression and OxS may be considered effective. Its protective effect may be attributable to a decrease of ROS production and an increase in antioxidant activity." This study had several limitations, including low number and high interindividual variability of examined subjects; and the severity on each relapse and the time between each one was not evaluated. Rajkumar et al (2023) states, "Humans are exposed to HMs through inhalation, ingestion, or contact with the skin. Environmental pollution with HMs can result in contamination of air, water, sewage, seawater, waterways, and can accumulate in plants, crops, seafood, and meat and indirectly affect humans. Some occupations have increased risk for particular HMs exposure and toxicity. Some HMs can cause toxicity even at very low concentrations and are known as non-threshold HMs. Factors influencing the risk of toxicity include age, body weight, genetics, route of acquisition, duration of exposure, amount, health, nutritional status, and a combination of HMs. Some preparations used in complementary medicine can result in toxicity. Management includes preventing any further exposure, removal of the offending agent using chelating agents, supportive therapy, and patient education." Song, Zhang (2020) states, "Ethylene diamine tetra-acetic acid (EDTA) is a chelating agent binding to calcium, lead, iron, and copper, among other metal ions to form solvable complexes and facilitate their urinary excretion. EDTA chelation therapy has been utilized in patients with atherosclerotic cardiovascular disease on the foundation that calcium chelation could alleviate atherosclerotic plaque with calcium. However, the current pool of evidence of EDTA chelation therapy to treat in atherosclerotic cardiovascular disease remains controversial." Baldari et al (2020) states, "Unfortunately, the limited current knowledge of the complex mechanisms regulating neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, and of the precise role or consequences of the mechanisms specifically dysregulated by copper imbalance in these brain pathologies have led to a minor success of the use of copper chelating agents for the treatment of these diseases. Further randomized clinical trials are necessary to confirm the benefit observed in preclinical models."

## POSITION STATEMENT:

Chelation therapy **meets the definition of medical necessity** when administered for the treatment of the following:

- Extreme conditions of metal toxicity
- Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) or due to non-transfusion-dependent thalassemia
- Disorders of copper metabolism (e.g., Wilson's disease)

- Lead poisoning (acute or long-term)
- Control of ventricular arrhythmias or heart block associated with digitalis toxicity
- Emergency treatment of hypercalcemia
- Aluminum overload in individuals with end-stage renal disease (ESRD)

Chelation therapy is considered **experimental or investigational**, as there is insufficient scientific evidence to support the use of chelation therapy for all other indications, and specifically for the following conditions:

- Atherosclerosis (e.g., coronary artery disease, secondary prevention in individuals with myocardial infarction, cerebrovascular disease, peripheral vascular disease)\*
- Multiple sclerosis
- Arthritis (includes rheumatoid arthritis)
- Hypoglycemia
- Diabetes
- Autism
- Pervasive developmental disorders (PDD)
- Cancer
- Alzheimer's disease
- Treatment of "mercury toxicity" thought to be from dental amalgam fillings

### BILLING/CODING INFORMATION:

The following codes may be used to describe chelation therapy.

#### HCPCS Coding:

J0470	Injection, dimercaprol, per 100 mg
J0600	Injection, edetate calcium disodium, up to 1000 mg
J0895	Injection, deferoxamine mesylate, 500 mg
J3520	Edetate disodium, per 150 mg (Endrate, EDTA)
M0300	IV chelation therapy (chemical endarterectomy)

#### ICD-10 Diagnosis Codes That Support Medical Necessity for J0470, J0600, J0895, J3520, and M0300:

D46.Z	Other myelodysplastic syndromes
D46.9	Myelodysplastic syndrome, unspecified
D56.0 – D56.9	Thalassemia
D57.40 – D57.459	Sickle-cell thalassemia
D64.0 – D64.4	Other anemias
E83.00 – E83.09	Disorders of copper metabolism
E83.10 – E83.19	Disorders of iron metabolism
E83.2	Disorders of zinc metabolism

E83.52	Hypercalcemia
T45.4x1A – T45.4X4S	Poisoning by iron and its compounds
T56.0x1A – T56.0x4S	Toxic effects of lead and its compounds
T56.1x1A – T56.1x4S	Toxic effect of mercury and its compounds
T56.2x1A – T56.2x4S	Toxic effect of chromium and its compounds
T56.3x1A – T56.3x4S	Toxic effect of cadmium and its compounds
T56.4x1A – T56.4x4S	Toxic effect of copper and its compounds
T56.5x1A -- T56.5x4S	Toxic effect of zinc and its compounds
T56.6x1A -- T56.6x4S	Toxic effect of tin and its compounds
T56.7x1A -- T56.7x4S	Toxic effects of beryllium and its compounds
T56.811A -- T56.814S	Toxic effect of thallium
T56.891A -- T56.894S	Toxic effects of other metals
T56.91XA -- T56.94XS	Toxic effect of unspecified metal
T57.0x1A – T57.0x4S	Toxic effect of arsenic and its compounds

## REIMBURSEMENT INFORMATION:

Refer to sections entitled [POSITION STATEMENT](#).

## PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage products:** The following National Coverage Determinations (NCDs) were reviewed on the last guideline reviewed date: Chelation Therapy for Treatment of Atherosclerosis (20.21) and Ethylenediamine-Tetra-Acetic (EDTA) CHELATION Therapy for Treatment of Atherosclerosis (20.22), located at [cms.gov](http://cms.gov).

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

## DEFINITIONS:

**Transfusional hemosiderosis:** accumulation of iron in internal organs that results from repeated blood transfusions.

**Wilson’s disease:** abnormal processing of copper in the body, causing copper accumulation.

## RELATED GUIDELINES:

None applicable.

## OTHER:

None applicable.

## REFERENCES:

1. American Academy of Pediatrics Policy Statement. Lead Exposure in Children: Prevention, Detection, and Management. *Pediatrics* 2005; 116; 1036-1046.
2. American Academy of Pediatrics. Treatment Guidelines for Lead Exposure in Children. *PEDIATRICS* Vol. 116 No. 4 October 2005, pp. 1036-1046 (DOI: 10.1542/peds.2005 – 1947).
3. American Cancer Society; Alternative and Complementary Therapies: Chelation Therapy.
4. American College of Cardiology Position Statement. Chelation Therapy: ACCF Complementary Medicine Expert Consensus Document: “Integrating Complementary Medicine into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)”. *Journal of the American College of Cardiology* Vol. 46, No. 1, 2005.
5. Aydinok Y. Combination chelation therapy. *Ann N Y Acad Sci.* 2023 Nov;1529(1):33-41. doi: 10.1111/nyas.15052. Epub 2023 Aug 18.
6. Baldari S, Di Rocco G, Toietta G. Current Biomedical Use of Copper Chelation Therapy. *Int J Mol Sci.* 2020;21(3):1069. Published 2020 Feb 6. doi:10.3390/ijms21031069.
7. Blue Cross Blue Shield Association Evidence Positioning System®. 8.01.02 - Chelation Therapy for Off-Label Uses, 03/25.
8. Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Bova C, Filippelli G, Capodanno I, Neri A, Morabito F, Gentile M, Vigna E. Iron chelation therapy. *Eur J Haematol.* 2023 May;110(5):490-497. doi: 10.1111/ejh.13935. Epub 2023 Feb 8.
9. Carter JA, Desai SM, Probst J, Kogan M. Integrative Medicine Approach To Peripheral Neuropathy-Avoiding Pitfalls Of Ineffective Current Standards In Assessing Chronic Low-Grade Mercury Toxicity And Functional Musculoskeletal Lesions. *Integr Med (Encinitas).* 2019 Oct;18(5):49-55.
10. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD) L29098 Chelation Therapy (02/02/09). (Retired 09/30/15).
11. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD) L33809 Chelation Therapy (10/01/15). (Retired 08/11/17).
12. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) for CHELATION Therapy for Treatment of Atherosclerosis (20.21) (Longstanding; no posted effective date).
13. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) for Ethylenediamine-Tetra-Acetic (EDTA) CHELATION Therapy for Treatment of Atherosclerosis (20.22) (Longstanding; no posted effective date).
14. Charlton N, Wallace KL. American College of Medical Toxicology Position Statement on Post-Chelator Challenge Urinary Metal Testing (2009). Accessed at <http://www.acmt.net>.
15. Chen KH, et al. Effect of Chelation Therapy on Progressive Diabetic Nephropathy in Patients with Type 2 Diabetes and High-Normal Body Lead Burdens. *Am J Kidney Dis.* 2012;60(4):530-538.
16. ClinicalTrials.gov. Trial to Assess Chelation Therapy (TACT). Information provided by National Heart, Lung, and Blood Institute (NHLBI). Identifier NCT00044213.
17. Crinnion WJ. The benefits of pre- and post-challenge urine heavy metal testing: Part 1. *Altern Med Rev.* 2009 Mar;14(1):3-8.

18. Crinnion WJ. The benefit of pre- and post-challenge urine heavy metal testing: Part 2. *Altern Med Rev.* 2009 Jun;14(2):103-8.
19. HAYES, Inc. Medical Technology Directory. Chelation Therapy, Non-Overload Conditions. Lansdale, PA. Hayes, Inc.; (10/05/04; updated 11/04/07).
20. HAYES, Inc. Medical Technology Directory: Chelation Therapy, Overload Conditions. Lansdale, PA. Hayes, Inc.; (02/28/03; updated 03/27/08).
21. Ho G, et al. Blood, Urine, and Hair Kinetic Analysis Following an Acute Lead Intoxication. *Journal of Analytical Toxicology*, Vol. 35, January/February 2011.
22. Kianoush S, Sadeghi M, Balali-Mood M. Recent Advances in the Clinical Management of Lead Poisoning. *Acta Med Iran.* 2015;53(6):327-36.
23. Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. *Drug Des Devel Ther.* 2016 Jan 29; 10:465-81.
24. Qaseem A, et al. Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Ann Intern Med.* 2012; 157:735-743.
25. Rajkumar V, Lee VR, Gupta V. Heavy Metal Toxicity. [Updated 2023 Mar 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560920/>
26. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. *Cochrane Database of Systematic Reviews* 2008, Issue 1. Art. No.: CD005380. DOI: 10.1002/14651858.CD005380.pub3.
27. Smith HJ, Meremikwu M." Iron chelating agents for treating malaria"; a review published in *The Cochrane Library* 2007, Issue 2.
28. Song T, Zhang D. Evaluation on curative effects of ethylene diamine tetra-acetic acid chelation therapy in treating with atherosclerotic cardiovascular disease: A protocol for systematic review and meta-analysis. *Medicine (Baltimore).* 2020 Dec 24;99(52): e23346. doi: 10.1097/MD.00000000000023346.
29. Taher AT, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. *Blood Cells Mol Dis.* 2016 Mar; 57:23-9.
30. UpToDate. Autism spectrum disorder in children and adolescents: Complementary and alternative therapies. 2025. Accessed at [uptodate.com](https://www.uptodate.com).
31. UpToDate. Childhood lead poisoning: Management. 2025. Accessed at [uptodate.com](https://www.uptodate.com).
32. UpToDate. Iron chelators: Choice of agent, dosing, and adverse effects. 2025. Accessed at [uptodate.com](https://www.uptodate.com).
33. UpToDate. Lead exposure and poisoning in adults: Management. 2025. Accessed at [uptodate.com](https://www.uptodate.com).
34. UpToDate. Management of thalassemia. 2025. Accessed at [uptodate.com](https://www.uptodate.com).
35. UpToDate. Prevention of cardiovascular disease events in those with established disease (secondary prevention). 2025. Accessed at [uptodate.com](https://www.uptodate.com).
36. Vezzoli A, Mrakic-Spota S, Dellanoce C, Montorsi M, Vietti D, Ferrero ME. Chelation Therapy Associated with Antioxidant Supplementation Can Decrease Oxidative Stress and Inflammation in Multiple Sclerosis: Preliminary Results. *Antioxidants (Basel).* 2023 Jun 24;12(7):1338. doi: 10.3390/antiox12071338.

37. Villarruz MV, Dans A, Tan F. "Chelation therapy for atherosclerotic cardiovascular disease"; a review published in The Cochrane Library 2006, Issue 2.
38. Villarruz-Sulit MV, Forster R, Dans AL, Tan FN, Sulit DV. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database Syst Rev. 2020;5(5):CD002785. Published 2020 May 5. doi: 10.1002/14651858.CD002785.pub2. PMID: 32367513.
39. WHO guideline for clinical management of exposure to lead: executive summary. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

## COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 02/22/26.

## GUIDELINE UPDATE INFORMATION:

08/15/01	Medical Coverage Guideline Reformatted.
09/15/02	Reviewed; references updated. Added Program Exception for Medicare and More.
10/15/03	Reviewed; add iron overload as a covered diagnosis.
07/15/04	Scheduled review; no changes.
08/15/05	Scheduled review; no change in coverage statement.
08/15/06	Scheduled review; revise coverage statement regarding acute iron intoxication and chronic iron overload.
11/15/06	Revision consisting of adding clarification statement regarding testing for lead toxicity.
07/15/07	Scheduled review; added ICD-9 code to Program Exception for Medicare Advantage products; reformatted guideline; updated references.
09/15/08	Scheduled review; no change in position statement. Update references.
09/15/09	Scheduled review; no change in position statement. Update references.
10/01/10	4th Quarter HCPCS coding update: ICD-9 diagnosis code 275.0 deleted; ICD-9 diagnosis codes 275.01, 275.02, 275.03 and 275.09 added.
10/15/10	Revision; related ICD-10 codes added; Medicare Exception ICD-9 coding section updated with the addition of ICD-9 codes 275.01 – 275.09 for CPT code J0895.
10/01/11	Revision; added ICD9 codes 282.43, 282.44 and 282.45.
05/15/14	Unscheduled review. Revised MCG title, description section, position statement, ICD9 and ICD10 coding, program exceptions and definitions. Updated references.
10/01/15	Revision consisting of update to Program Exceptions section.
11/01/15	Revision: ICD-9 Codes deleted.
09/15/18	Scheduled review. Minor verbiage revisions regarding coverage of iron overload and lead poisoning. Updated program exceptions section and references.
08/15/20	Scheduled review. Maintained position statement. Revised description, ICD10 coding, and definitions. Updated references.
10/01/20	Annual ICD10 coding update. Added codes D57.42, D57.43, D57.431, D57.432, D57.433, D57.438, D57.439, D57.44, D57.45, D57.451, D57.452, D57.453, D57.458, D57.459.
05/15/22	Scheduled review. Add coverage statement for mercury toxicity and dental amalgam. Update references.
05/22/23	Update to Program Exceptions section.

03/15/24	Scheduled review. Revised description, maintained position statement, and updated references.
03/15/25	Scheduled review. Revised description, maintained position statement and updated references.
03/15/26	Scheduled review. Maintained position statement and updated references.